Show simple item record

dc.contributor.editorLipman, Jeffrey
dc.date.accessioned2021-05-01T15:40:53Z
dc.date.available2021-05-01T15:40:53Z
dc.date.issued2020
dc.identifierONIX_20210501_9783039431229_835
dc.identifier.urihttps://directory.doabooks.org/handle/20.500.12854/69089
dc.description.abstractThere has been much speculation about a possible antibiotic Armageddon; this would be the result of having untreatable post-operative infections, and similarly untreatable complications after chemotherapy. The now famous “O’Neill Report” (https://amr-review.org/) suggests that more people could die from resistant bacterial infections by 2050 than from cancer. We are still learning about all the subtle drivers of antibiotic resistance, and realizing that we need a single “whole of health” co-ordinated policy. We ingest what we sometimes feed to animals. There do not seem to be any new classes of antibiotics on our horizon. Perhaps something that has been around “forever” will come to our rescue—bacteriophages! Nevertheless, we have to do things differently, use antibiotics appropriately, for the correct indication, for the correct duration and with the correct dose, and with that, practice good antibiotic stewardship. Whilst by no means comprehensive, this book does cover some of the many topics of antibiotic stewardship. It also addresses some of the older antibiotics, some new combinations, and even some new agents. Last, and by no means least, there are two excellent articles on bacteriophages.
dc.languageEnglish
dc.subject.classificationthema EDItEUR::M Medicine and Nursingen_US
dc.subject.otherAntimicrobial resistance
dc.subject.otherantibiotics
dc.subject.otherantimicrobial stewardship
dc.subject.otherinappropriate prescribing
dc.subject.otherdays of therapy
dc.subject.otherStart Smart then Focus
dc.subject.otherpiperine
dc.subject.otherpiperlongumine
dc.subject.otherantibacterial
dc.subject.otherantifungal
dc.subject.othersynergy
dc.subject.othernon-target feed
dc.subject.otherflorfenicol
dc.subject.otherthiamfenicol
dc.subject.otherchloramfenicol
dc.subject.otherHPLC–MS/MS
dc.subject.othervalidation
dc.subject.otherswine
dc.subject.otherout-of-hours care
dc.subject.otherprimary care
dc.subject.otherquality of care
dc.subject.otherquality indicators
dc.subject.otherpractitioners cooperative
dc.subject.otherantibiotic stewardship
dc.subject.otherfluoroquinolones
dc.subject.otherguidelines
dc.subject.otherurinary tract infections
dc.subject.otherquality improvement
dc.subject.othergeneral practitioners
dc.subject.otherguideline
dc.subject.otherhealth inequalities
dc.subject.otherhealth equity assessment tool
dc.subject.otherpublic health
dc.subject.otherEnterobacteriaceae
dc.subject.othercarbapenem-resistant
dc.subject.otherCRE
dc.subject.otherantibiotic resistance
dc.subject.otherantimicrobials
dc.subject.otherbacteriophages
dc.subject.otherbiofilms
dc.subject.othernovel antimicrobials
dc.subject.otherAntibiotics
dc.subject.otherresistance
dc.subject.otherbroad-spectrum agents
dc.subject.otherhospital epidemiology
dc.subject.otherantibiotic utilization
dc.subject.otherinfection control
dc.subject.otherinfection prevention
dc.subject.otherPseudomonas aeruginosa
dc.subject.otherAcinetobacter baumannii
dc.subject.otherextended-spectrum beta-lactamases
dc.subject.othercarbapenem-resistant Enterobacteriaceae
dc.subject.othermethicillin-resistant Staphylococcus aureus
dc.subject.otherclinical trials
dc.subject.otherinfectious disease
dc.subject.otherphage therapy
dc.subject.othersilver complexes
dc.subject.othercamphorimine
dc.subject.otheranti-Candida activity
dc.subject.otherantifungals
dc.subject.otherantibacterials
dc.subject.otherefflux inhibitors
dc.subject.otherefflux pumps
dc.subject.othererm(41)
dc.subject.othermutations
dc.subject.othermycobacteria
dc.subject.otherverapamil
dc.subject.otheractinomycetes
dc.subject.otherbioactivity
dc.subject.otherpolyketides
dc.subject.otherpolyketide synthases
dc.subject.otherbiosynthesis
dc.subject.otherantimicrobial resistance
dc.subject.othereconomic evaluation
dc.subject.othercost-utility analysis
dc.subject.othercost-effectiveness analysis
dc.subject.otherpolicy analysis
dc.subject.otherOne Health
dc.subject.otherSingapore
dc.subject.otherantibiotic prescribing
dc.subject.otherimplementation
dc.subject.otherbehavior change
dc.subject.otherstakeholder consultation
dc.subject.othern/a
dc.titleFeature Paper in Antibiotics for 2019
dc.typebook
oapen.identifier.doi10.3390/books978-3-03943-123-6
oapen.relation.isPublishedBy46cabcaa-dd94-4bfe-87b4-55023c1b36d0
oapen.relation.isbn9783039431229
oapen.relation.isbn9783039431236
oapen.pages282
oapen.place.publicationBasel, Switzerland


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0/